The TNF-α gene encodes a critical pro-inflammatory cytokine that orchestrates immune responses and inflammatory cascades. The AG genotype of rs1800629 is associated with intermediate TNF-α production levels, positioned between the low-producing GG and high-producing AA genotypes. This moderately increased TNF-α expression can still contribute to autoimmune dysregulation by enhancing inflammatory signaling, promoting B and T cell activation, and potentially disrupting self-tolerance mechanisms. The intermediate increase in TNF-α production may partially explain inflammatory biomarker patterns like elevated homocysteine and reduced adiponectin, as TNF-α can both impair homocysteine metabolism and suppress adiponectin expression. This genotype represents a moderate genetic risk factor for developing or exacerbating autoimmune conditions with inflammatory components.

The TNFRSF1B gene encodes tumor necrosis factor receptor 2 (TNFR2), which plays a crucial role in mediating TNF-α signaling for cell survival, proliferation, and inflammatory responses. The TG genotype of rs1061622 represents a heterozygous state that results in intermediate alteration of TNFR2 function and shedding. With one copy of the risk allele, individuals have partially reduced capacity to generate soluble TNFR2, which normally acts to neutralize circulating TNF-α. This moderately impaired neutralization allows for somewhat prolonged TNF-α activity and enhanced inflammatory signaling compared to the TT genotype. The resulting moderate increase in inflammatory potential can contribute to autoimmune dysregulation and may influence homocysteine metabolism and adiponectin production, potentially contributing to the observed biomarker patterns in your condition.

The IL6 gene produces interleukin-6, a pleiotropic cytokine that regulates immune responses, inflammation, and acute phase reactions. The GC genotype of rs1800795 represents a heterozygous state associated with intermediate IL-6 production levels, positioned between the low-producing GG and high-producing CC genotypes. This moderately increased IL-6 expression can contribute to autoimmune dysregulation by enhancing B cell differentiation, antibody production, and T cell activation to an intermediate degree. The resulting moderate increase in inflammatory potential can affect homocysteine metabolism and suppress adiponectin production, potentially contributing to the observed biomarker patterns in your condition. This genotype represents a moderate genetic risk factor for developing or exacerbating autoimmune conditions with inflammatory components, including incomplete lupus.

This SNP is located in the promoter region of the TNF gene, which encodes tumor necrosis factor alpha, a potent pro-inflammatory cytokine central to immune regulation and inflammatory responses. The TT genotype is associated with increased TNF-α production compared to the CC genotype. This heightened TNF-α expression promotes excessive inflammatory responses and can contribute to autoimmune dysregulation through enhanced activation of inflammatory pathways, increased recruitment and activation of immune cells, and potential disruption of immune tolerance mechanisms. The elevated TNF-α levels directly contribute to systemic inflammation and can affect multiple tissues, potentially explaining symptoms like fatigue, muscle pain, and depression through direct and indirect inflammatory effects. This genotype is consistent with your elevated homocysteine levels, as TNF-α can impair homocysteine metabolism, and with your low adiponectin, as TNF-α suppresses adiponectin production.

The IL1B gene produces interleukin-1 beta, a key pro-inflammatory cytokine that initiates and amplifies inflammatory cascades. The AG genotype of rs1143634 represents a heterozygous state associated with intermediate IL-1β production levels, positioned between the lower-producing GG and higher-producing AA genotypes. This moderately increased IL-1β expression can contribute to autoimmune dysregulation by enhancing inflammatory signaling, immune cell activation, and potentially disrupting tissue homeostasis to an intermediate degree. The resulting moderate increase in inflammatory potential can affect homocysteine metabolism and suppress adiponectin production, potentially contributing to the observed biomarker patterns in your condition. This genotype represents a moderate genetic risk factor for developing or exacerbating autoimmune conditions with inflammatory components.

This SNP (also known as TaqIA) is located near the DRD2 gene, which encodes the dopamine D2 receptor involved in dopamine signaling in the brain. The AA genotype (also referred to as A1/A1) is associated with significantly reduced dopamine D2 receptor density and altered dopamine signaling. While primarily studied in the context of neuropsychiatric conditions, this variant has relevance to autoimmune dysregulation through neuroimmune interactions. Reduced dopamine signaling can enhance inflammatory responses, as dopamine normally exerts anti-inflammatory effects on immune cells through dopamine receptors expressed on T cells, B cells, and macrophages. The altered dopamine signaling with this genotype can contribute to immune dysregulation by reducing this anti-inflammatory influence, potentially exacerbating autoimmune processes and inflammatory responses. This mechanism may contribute to neuroinflammation and symptoms like depression, anxiety, and fatigue, which are prominent in your presentation.